Tiotropium HandiHaler in the treatment of COPD: a safety review
about
Tiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseTiotropium versus placebo for chronic obstructive pulmonary diseaseTiotropium versus ipratropium bromide for chronic obstructive pulmonary diseaseTiotropium versus placebo for chronic obstructive pulmonary diseaseComorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary diseaseDifferential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterolTiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysisRisk of acute urinary retention associated with inhaled anticholinergics in patients with chronic obstructive lung disease: systematic review.Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease.Management of patients during and after exacerbations of chronic obstructive pulmonary disease: the role of primary care physicians.Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD.Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular riskSafety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trialSafety and tolerability of inhalational anticholinergics in COPDEffect of inhaled drugs on anxiety and depression in patients with chronic obstructive pulmonary disease: a prospective observational study.Early intervention with tiotropium in Chinese patients with GOLD stages I-II chronic obstructive pulmonary disease (Tie-COPD): study protocol for a multicentre, double-blinded, randomised, controlled trial.NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.Safety of chronic obstructive pulmonary disease medications: a primary care perspective.Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease.The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease.Indacaterol-induced severe constipation and abdominal pain: is there a role for colonic β3-adrenoceptors?Skin reaction to inhaled tiotropium bromide: a case reportBronchodilator Effect of Tiotropium via Respimat®Administered with a Spacer in Patients with Chronic Obstructive Pulmonary Disease (COPD).Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.[COPD-Management, a comprehensive review].
P2860
Q24187073-CBBC146B-D881-4C74-82BB-1290BFEAF313Q24194833-51A4AF7E-408B-4EFB-B516-530A8D1F6E22Q24198068-2F44DFDE-8EC9-4821-8CF0-B79966A26907Q24202175-5DEC2BBA-355D-4CED-8BAA-23BA45D6CA4EQ26823339-988C2D19-A975-4EAA-A5B1-8DE35D0DC7A7Q26828602-C687374E-8903-4DAA-9740-BEA956A177A0Q30620671-0197166C-8250-4D46-906F-FCA5F82FC1F3Q33698524-44238548-09E6-47FB-A8E0-4D7270BE18A3Q33949299-CE94C1C3-A9C5-40CA-AE10-69555EE929AEQ34309072-72D588B3-A661-4DE3-A5CB-B64AF8209A8CQ35225129-F7DB0400-8DCD-40AC-A17B-C6AC5B472404Q35695190-B264F308-E285-4A6B-82BE-89AEC95F8CC2Q35999260-6A726FDA-416C-4439-8E81-B05E7824683EQ36412770-876E6C8C-0C79-4B95-BEAF-B25E712521DBQ36456873-C7550DD6-6DBA-4C06-9F23-2F78DCBC8964Q36680246-C9F9100A-6535-44C6-B75F-1412364AE521Q36802786-54486195-BA7D-4932-803E-6CA8C40D2AF9Q37598054-266D3682-AA3D-4A37-A347-4D70CEC8E678Q37867838-005B5515-22BC-4785-A585-F12C9AEAB8BEQ37874890-E09DAA67-4032-4AE7-8A14-BAC52954C69EQ37973132-A900D82E-E3C1-4754-AD03-9BB0FFC132EFQ38258538-E474CB92-5704-4C6D-A313-280B2C8D4091Q38592062-7749E7AB-19A9-47EA-B49E-B89623AEB201Q41368046-1B93996C-4CE7-4063-B6DE-A50F817E34F0Q41790575-C9BA8AEC-98E5-445E-90BA-5B7294623258Q42378735-DC65A884-8A41-465E-B1FD-02485851CA42Q43997723-F4E60D4A-0F7F-4634-A8FA-8E4FFFC27018Q51791945-C2F184A1-523A-4AE1-9B42-CCE0BBF17CF0
P2860
Tiotropium HandiHaler in the treatment of COPD: a safety review
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Tiotropium HandiHaler in the treatment of COPD: a safety review
@en
Tiotropium HandiHaler in the treatment of COPD: a safety review.
@nl
type
label
Tiotropium HandiHaler in the treatment of COPD: a safety review
@en
Tiotropium HandiHaler in the treatment of COPD: a safety review.
@nl
prefLabel
Tiotropium HandiHaler in the treatment of COPD: a safety review
@en
Tiotropium HandiHaler in the treatment of COPD: a safety review.
@nl
P2093
P2860
P921
P356
P1476
Tiotropium HandiHaler in the treatment of COPD: a safety review.
@en
P2093
Bart Celli
Donald Tashkin
Inge Leimer
Steven Kesten
P2860
P304
P356
10.2147/COPD.S4802
P407
P577
2009-11-29T00:00:00Z